LOS ANGELES, CA--(Marketwired - Jul 15, 2013) - MMRGlobal, Inc. (OTCQB: MMRF), through its wholly owned subsidiary MyMedicalRecords, Inc. (collectively, "MMR"), today announced that it has received an Issue Notification from the United States Patent and Trademark Office for U.S. Patent No. 8,498,883 (the "883 patent") entitled, "Method for Providing a User with a Service for Accessing and Collecting Prescriptions." The 883 patent will have 28 claims which are directed toward providing a user with the ability to access and manage prescriptions online by providing features that include sending prescriptions to a pharmacy, accessing prescriptions from a pharmacy, scheduling prescription refills, sending reminders regarding prescription refills including by text or email, and identifying adverse drug interactions by analyzing prescription medications. Prior to the issuance of the 833 patent, MMR's health information technology patent portfolio consists of seven issued U.S. patents, including U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; and 8,321,240, as well as additional applications and continuation applications involving inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. 

MMR is a leading provider of Personal Health Record (PHR) products and services which it sells direct-to-consumers, healthcare professionals, employers, membership organizations and others. According to Robert H. Lorsch, MMRGlobal CEO, "If anyone has a question about the importance of maintaining a Personal Health Record, all they have to do is follow the news. An article in the Los Angeles Times on Friday underscored the importance of patient control of a family's personal health information which is the very essence of what our products and services do and what our underlying IP was invented to protect. We offer a Personal Health Record service (www.mmrvideos.com) that was built to allow patients to make the choice of who can access their most private and personal medical records and important documents. Had the individuals, celebrities and personalities who have had their medical records improperly accessed, had they been stored in a secure patient-controlled MyMedicalRecords.com account, they might have been the only ones able to leak them to the media. No one should have access to your VIP (Very Important Patient) health records, except you and authorized members of your family."

Based on trends offering consumers the ability to manage prescriptions online, MMR believes the 883 patent to be a significant addition to its existing U.S. patent portfolio. This will bring the number to eight U.S. health information technology patents with more than 400 claims and is extremely relevant to MMR's business of selling its products and services and/or licensing its patented intellectual property to healthcare professionals and others including retail pharmacies.

After MMR's efforts to offer its products and services to Walgreens last January, MyMedicalRecords, Inc. filed a patent infringement complaint against Walgreen Co. for infringement of its Personal Health Records patent, 8,301,466. According to a July 1st press release issued by MMRGlobal, MMR will seek a stipulation or leave of court to amend the Walgreen complaint to include claims for infringement of the 833 patent.

MMR's health IT patent portfolio also includes 21 other pending U.S. applications in addition to issued patents and pending applications in other countries of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, China, Hong Kong, South Korea, Israel, and European nations.

Additionally, MMRGlobal owns biotechnology intellectual property separate from its health IT portfolio as a result of its reverse merger with Favrille, Inc., a biopharmaceutical company, in January 2009. More than $100 million was invested on research and development of its FavId™/Specifid™ vaccine trials and use of customized tumor cells to treat lymphoma patients and other technologies. MMR's biotech assets include an extensive portfolio including its anti-CD20 monoclonal antibodies, data from vaccine trials, thousands of patient tumor samples and other intellectual property which the Company has already licensed to a major pharmaceutical company under a $13 million non-exclusive licensing agreement of which approximately $12 million remains unpaid.

About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. MMR's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, MMR acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of MMR's products and services at www.mmrtheater.com.

Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMR's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both MMR's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk MMR's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in MMR's filings with the Securities and Exchange Commission. MMR is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact Information:


Michael Selsman
Public Communications Co.
(310) 922-7033